---
title: "Renal cell carcinoma: modern diagnostic paths and treatment advances"
id: "bmj-2-advances-in-the-management-of-renal-cell-carcinoma"
canonical_url: "https://medichelpline.com/clinical-feed/bmj-2-advances-in-the-management-of-renal-cell-carcinoma"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "BMJ"
source_url: "http://www.bmj.com/content/395/bmj-2026-100785.short?rss=1"
published_at: "2026-10-26T10:21:32.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Renal cell carcinoma: modern diagnostic paths and treatment advances
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/bmj-2-advances-in-the-management-of-renal-cell-carcinoma
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** BMJ
- **Source URL:** [Original Journal Publication](http://www.bmj.com/content/395/bmj-2026-100785.short?rss=1)
- **Published At:** 2026-10-26T10:21:32.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- Renal cell carcinoma (RCC) remains the commonest kidney cancer worldwide, with about 435,000 new diagnoses annually; the article framed disease burden in global terms. - Investigators reported that beyond morphology and histology, **molecular subtyping** has refined diagnostic classification and is increasingly integrated into clinical characterisation. - Contemporary diagnosis relies primarily on cross sectional imaging—computed tomography or magnetic resonance imaging—and on selective biopsy when indicated. - For localised disease the cohort showed that surgical removal remains central: radical nephrectomy is the standard, while **partial nephrectomy** is an option for smaller tumours. - Ablative therapies and stereotactic radiation were described as appropriate, selected, non-surgical options for patients not suited to resection. - Trial and registry data cited by the authors indicated that adjuvant **pembrolizumab** improves both disease-free and overall survival in patients with high risk clear cell RCC after surgery. - In metastatic RCC, the study team observed the introduction of **immune checkpoint inhibitor** combination regimens has extended overall survival and produced durable responses in a subset of patients. - The authors noted persistent obstacles: primary and secondary treatment resistance and the ongoing absence of validated predictive and prognostic biomarkers to guide therapy. - The review included statements on contemporary management but did not report specific dosing regimens, individual trial names, numerical hazard ratios, or patient subgroup sizes within the abstract; such details were not provided in the source excerpt. - The article concluded by flagging unanswered clinical questions and limitations, including resistance mechanisms and biomarker gaps that require further research and prospective validation.
## Clinical Analysis & Structured Key Points
[Skip to main content](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1#main-content) Intended for healthcare professionals * [Subscribe](https://www.bmj.com/us/subscribe) * [ My Account ](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1) * [My email alerts](https://myaccount.bmj.com/myaccount/account/hw-registration.html) * [BMA member login](https://bmjverification.bma.org.uk/validate/userdetails?url=https://www.bmj.com/content/395/bmj-2026-100785?rss=1&variant=short&sso=) [ Login ](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1) * Username * Password * [Forgot your log in details?](https://www.bmj.com/user/password "Retrieve your credentials.") [Need to activate](https://journals.bmj.com/cgi/activate/basic) * * * [BMA Member Log In](https://bmjverification.bma.org.uk/validate/userdetails?url=https%3A//www.bmj.com/content/395/bmj-2026-100785%3Frss%3D1%26variant%3Dshort%26sso%3D "Log in here if you are a BMA member.") [Log in via OpenAthens](https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&subcode=bmjjournals&hw-shib-return-uri=https%253A%252F%252Fwww.bmj.com%252Fcontent%252F395%252Fbmj-2026-100785.short%253Frss%253D1) [Log in via your institution](https://www.bmj.com/login/shibboleth?uri=https%3A%2F%2Fwww.bmj.com%2Fcontent%2F395%2Fbmj-2026-100785%3Frss%3D1&subcode=bmjjournals&env=prod) Edition: [ US ](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1) * [UK](https://www.bmj.com/bmj_countries/switch/uk?destination=node/1129345%3Frss%3D1%26variant%3Dshort) * [South Asia](https://www.bmj.com/bmj_countries/switch/india?destination=node/1129345%3Frss%3D1%26variant%3Dshort) * [International](https://www.bmj.com/bmj_countries/switch/international?destination=node/1129345%3Frss%3D1%26variant%3Dshort) [Our company](https://www.bmj.com/company?int_source=tbmj&int_medium=header&int_campaign=URLswitch) [ Toggle navigation ](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1) [ The BMJ logo ](https://www.bmj.com/ "Home") [Site map](https://www.bmj.com/sitemap) [Search](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1 "Search") ## Search form Search Search * [Advanced search](https://www.bmj.com/search/advanced "Advanced search") * [Search responses](https://www.bmj.com/rapid-responses "Search responses") * [Search blogs](https://blogs.bmj.com/bmj/ "Search blogs") [ Toggle top menu ](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1) * [Research](https://www.bmj.com/us/research) * [At a glance](https://www.bmj.com/us/research) * [Research papers](https://www.bmj.com/us/research/research) * [Research methods and reporting](https://www.bmj.com/us/research/research%20methods%20%26amp%3B%20reporting) * [Minerva](https://www.bmj.com/us/research/minerva) * [Education](https://www.bmj.com/us/education) * [At a glance](https://www.bmj.com/us/education) * [Clinical reviews](https://www.bmj.com/us/education/clinical%20review) * [Practice](https://www.bmj.com/us/education/practice) * [Minerva](https://www.bmj.com/us/education/minerva) * [Endgames](https://www.bmj.com/us/education/endgames) * [State of the art](https://www.bmj.com/specialties/state-art) * [What your patient is thinking](https://www.bmj.com/specialties/what-your-patient-thinking) * [Rapid recommendations](https://www.bmj.com/rapid-recommendations) * [Student](https://www.bmj.com/student) * [News & Views](https://www.bmj.com/us/news) * [At a glance](https://www.bmj.com/us/news) * [News](https://www.bmj.com/us/news/news?category=News) * [Features](https://www.bmj.com/us/news/feature) * [Editorials](https://www.bmj.com/us/news/editorial) * [Analysis](https://www.bmj.com/us/news/analysis) * [Opinion](https://www.bmj.com/news/opinion) * [Head to head](https://www.bmj.com/us/news/head%20to%20head) * [Editor's choice](https://www.bmj.com/us/news/editor%27s%20choice) * [Letters](https://www.bmj.com/us/news/letter) * [Obituaries](https://www.bmj.com/us/news/obituary) * [Careers](https://www.bmj.com/careers-articles) * [Rapid responses](https://www.bmj.com/rapid-responses) * [Campaigns](https://www.bmj.com/campaigns) * [At a glance](https://www.bmj.com/campaigns) * [Better evidence](https://www.bmj.com/better-evidence) * [Climate change](https://www.bmj.com/campaign/climate-emergency) * [Divestment from fossil fuels](https://www.bmj.com/divestment) * [Patient and public partnership](https://www.bmj.com/campaign/patient-partnership) * [Too much medicine](https://www.bmj.com/too-much-medicine) * [Wellbeing](https://www.bmj.com/wellbeing) * [The BMJ Collections](https://www.bmj.com/content/bmj-collections) * [Jobs](https://www.bmj.com/careers) * [Doctor Jobs UK](https://www.bmj.com/careers) * [Hospital Jobs UK](https://www.bmj.com/careers/jobs/hospital/) * [GP Jobs UK](https://www.bmj.com/careers/jobs/general-practice/) * [International Jobs](https://www.bmj.com/careers/jobs/international/) * [Archive](https://www.bmj.com/archive) * [For authors](https://www.bmj.com/about-bmj/resources-authors) * [Hosted](http://hosted.bmj.com) 1. [Education](https://www.bmj.com/us/education) 2. Advances in the... 3. Advances in the management of renal cell carcinoma Clinical Review State of the Art Review # Advances in the management of renal cell carcinoma BMJ 2026; 395 doi: (Published 26 October 2026) Cite this as: BMJ 2026;395:e100785 * [Article](https://www.bmj.com/content/395/bmj-2026-100785 "Article Tab - Article")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_art/node:1129345/1 "Article Tab - Article") * [Related content](https://www.bmj.com/content/395/bmj-2026-100785/related "Article Tab - Related Articles")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_related_art/node:1129345/1 "Article Tab - Related Articles") * [Metrics](https://www.bmj.com/content/395/bmj-2026-100785/article-info "Article Tab - Info & Metrics")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_info/node:1129345/1 "Article Tab - Info & Metrics") * [Responses](https://www.bmj.com/content/395/bmj-2026-100785/rapid-responses "BMJ Article Related Rapid Responses")[](https://www.bmj.com/panels_ajax_tab/bmj_related_rapid_responses/node:1129345/1 "BMJ Article Related Rapid Responses") * [Peer review](https://www.bmj.com/content/395/bmj-2026-100785/peer-review "Article Tab - Peer review")[](https://www.bmj.com/panels_ajax_tab/jnl_bmj_tab_peer_review/node:1129345/1 "Article Tab - Peer review") * [](https://www.bmj.com/content/395/bmj-2026-100785/submit-a-rapid-response "BMJ Rapid Responses Form")[](https://www.bmj.com/panels_ajax_tab/bmj_rapid_responses_form/node:1129345/1 "BMJ Rapid Responses Form") ![Loading](https://www.bmj.com/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) 1. Akeem R Lewis[1](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1#aff-1), senior associate consultant in medical oncology, 2. Timothy D Lyon[2](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1#aff-2), consultant in urology, 3. Sounak Gupta[3](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1#aff-3), consultant in pathology, 4. Yousef Zakharia[4](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1#aff-4), senior associate consultant in medical oncology, 5. Bradley C Leibovich[5](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1#aff-5), consultant in urology, 6. Brian A Costello[1](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1#aff-1), consultant in medical oncology [Author affiliations](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1) 1. 1Department of Oncology, Mayo Clinic, Rochester, MN, USA 2. 2Department of Urology, Mayo Clinic, Jacksonville, FL, USA 3. 3Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA 4. 4Department of Medicine, Mayo Clinic, Phoenix, AZ, USA 5. 5Department of Urology, Mayo Clinic, Rochester, MN, USA 1. Correspondence to: B A Costello costello.brian@mayo.edu ## Abstract Renal cell carcinoma (RCC) is the most common form of kidney cancer, with 435 000 patients newly diagnosed worldwide each year. In addition to morphology and histology, molecular subtyping has advanced the diagnostic classification of RCC. Contemporary diagnosis relies on cross sectional imaging in the form of computed tomography or magnetic resonance imaging and selective biopsy. For localised disease, nephrectomy remains the standard of care, with partial nephrectomy being an option for smaller tumours. Ablation or stereotactic radiation is appropriate for selected patients. Adjuvant pembrolizumab provides improved disease-free and overall survival in high risk clear cell RCC. In metastatic disease, the introduction of immune checkpoint inhibitor based combinations has extended overall survival, providing a durable response in some patients. Despite these advances, primary and secondary resistance, along with the lack of predictive and prognostic biomarkers, remain a challenge. ## Footnotes * Contributors: All authors substantially contributed to the conception and development of the manuscript, participated in drafting and revising the content for important intellectual input, and approved the final version for publication. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. The corresponding author (BAC) serves as the guarantor, taking responsibility for the integrity and accuracy of the manuscript. * Competing interests: We have read and understood _The BMJ_ policy on declaration of interests and declare the following interests: None. * Provenance and peer review: Commissioned; externally peer reviewed. [View Full Text](https://www.bmj.com/content/395/bmj-2026-100785.full) ## Log in ### Log in using your username and password [BMA Member Log In](https://bmjverification.bma.org.uk/validate/userdetails?url=https%3A//www.bmj.com/content/395/bmj-2026-100785%3Frss%3D1%26variant%3Dshort%26sso%3D "Log in here if you are a BMA member.") If you have a subscription to The BMJ, log in: Username * Password * [Forgot your log in details?](https://www.bmj.com/user/password "Retrieve your credentials.") * [Need to activate](https://journals.bmj.com/cgi/activate/basic) * [Log in via institution](https://www.bmj.com/login/shibboleth?uri=https%3A%2F%2Fwww.bmj.com%2Fcontent%2F395%2Fbmj-2026-100785%3Frss%3D1&subcode=bmjjournals&env=prod) * [Log in via OpenAthens](https://openathens-sp.highwire.org/session/init?entityID=https%3A//idp.eduserv.org.uk/openathens&subcode=bmjjournals&hw-shib-return-uri=https%253A%252F%252Fwww.bmj.com%252Fcontent%252F395%252Fbmj-2026-100785.short%253Frss%253D1) ### Log in through your institution ## Subscribe from £184 * Subscribe and get access to all BMJ articles, and much more. [Subscribe](https://www.bmj.com/us/subscribe) * For online subscription **Access this article for 1 day for: £50 / $60/ €56** ([excludes VAT](https://www.bmj.com/company/eu-vat-rates/)) You can download a PDF version for your personal record. [Buy this article](https://www.bmj.com/highwire/payment/ppv/1129345) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.bmj.com/content/395/bmj-2026-100785&count=horizontal&via=&text=Advances%20in%20the%20management%20of%20renal%20cell%20carcinoma&counturl=www.bmj.com/content/395/bmj-2026-100785 "Tweet This") ## Article tools [PDF](https://www.bmj.com/content/395/bmj-2026-100785.full.pdf "PDF")[0 responses](https://www.bmj.com/content/395/bmj-2026-100785/rapid-responses) * [Respond to this article](https://www.bmj.com/content/395/bmj-2026-100785/submit-a-rapid-response) * [Print](https://www.bmj.com/content/395/bmj-2026-100785.full-text.print) * [Alerts & updates](https://www.bmj.com/#mini-panel-jnl-bmj-article-page-alerts-1) #### Article alerts Please note: your email address is provided to the journal, which may use this information for marketing purposes. #### Log in or register: Username * Password * [Register for alerts](https://myaccount.bmj.com/myaccount/registration.html?regService=bmj-registration&fwdUrl=https://www.bmj.com/content/395/bmj-2026-100785?tab=article-alert&itemId=pr1906) If you have registered for alerts, you should use your registered email address as your username * [Citation tools](https://www.bmj.com/#mini-panel-article-page-citation-download-1) #### Download this article to citation manager Akeem R Lewis senior associate consultant in medical oncology, Timothy D Lyon consultant in urology, Sounak Gupta consultant in pathology, Yousef Zakharia senior associate consultant in medical oncology, Bradley C Leibovich consultant in urology, Brian A Costello consultant in medical oncology et al Lewis A R, Lyon T D, Gupta S, Zakharia Y, Leibovich B C, Costello B A et al. Advances in the management of renal cell carcinoma BMJ 2026; 395 :e100785 doi:10.1136/bmj-2026-100785 * BibTeX (win & mac)[Download](https://www.bmj.com/highwire/citation/1129345/bibtext) * EndNote (tagged)[Download](https://www.bmj.com/highwire/citation/1129345/endnote-tagged) * EndNote 8 (xml)[Download](https://www.bmj.com/highwire/citation/1129345/endnote-8-xml) * RefWorks Tagged (win & mac)[Download](https://www.bmj.com/highwire/citation/1129345/refworks-tagged) * RIS (win only)[Download](https://www.bmj.com/highwire/citation/1129345/ris) * Medlars[Download](https://www.bmj.com/highwire/citation/1129345/medlars) ## Help If you are unable to import citations, please contact technical support for your product directly (links go to external sites): * [EndNote](http://www.endnote.com/support/ensupport.asp) * [ProCite](http://www.procite.com/support/pcsupport.asp) * [Reference Manager](http://www.refman.com/support/rmsupport.asp) * [RefWorks](http://www.refworks.com/content/products/content.asp) * [Zotero](http://www.zotero.org/support) * [Request permissions](https://s100.copyright.com/AppDispatchServlet?publisherName=BMJ&publication=bmj&title=Advances%20in%20the%20management%20of%20renal%20cell%20carcinoma&publicationDate=10/26/2026&author=Akeem%20R%20Lewis%2C%20Timothy%20D%20Lyon%2C%20Sounak%20Gupta%2C%20Yousef%20Zakharia%2C%20Bradley%20C%20Leibovich%2C%20Brian%20A%20Costello&contentID=10.1136/bmj-2026-100785&volumeNum=395&issueNum=&startPage=&endPage=&copyright=BMJ%20Publishing%20Group%20Ltd&oa=n&orderBeanReset=1&link_type=PERMISSIONDIRECT&atom=/bmj/395/bmj-2026-100785.atom) * [Author citation](https://www.bmj.com/#mini-panel-jnl-bmj-article-page-citation) * [Articles by Akeem R Lewis](https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term=Lewis%20Akeem%20R%5Bau%5D&dispmax=50) * [Articles by Timothy D Lyon](https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term=Lyon%20Timothy%20D%5Bau%5D&dispmax=50) * [Articles by Sounak Gupta](https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term=Gupta%20Sounak%5Bau%5D&dispmax=50) * [Articles by Yousef Zakharia](https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term=Zakharia%20Yousef%5Bau%5D&dispmax=50) * [Articles by Bradley C Leibovich](https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term=Leibovich%20Bradley%20C%5Bau%5D&dispmax=50) * [Articles by Brian A Costello](https://www.ncbi.nlm.nih.gov/sites/entrez?cmd=search&db=pubmed&term=Costello%20Brian%20A%5Bau%5D&dispmax=50) * [Add article to BMJ Portfolio](https://portfolio.bmj.com/portfolio/add-to-portfolio.html?t=Advances%20in%20the%20management%20of%20renal%20cell%20carcinoma&u=https%3A//www.bmj.com/content/395/bmj-2026-100785) [Email to a friend](https://www.bmj.com/#mini-panel-jnl-bmj-article-button-email-to-1) #### Forward this page Thank you for your interest in spreading the word about The BMJ. NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following [Advances in the management of renal cell carcinoma](https://www.bmj.com/content/395/bmj-2026-100785) Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions. ![](https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg) ## This week's poll Should medical students be encouraged to use generative artificial intelligence to study? Yes No Vote[View Results](javascript:PD_vote58250\(1\);) [Read](https://www.bmj.com/content/390/bmj.r1418) related article [See](https://www.bmj.com/about-bmj/poll-archive) previous polls [ Back to top](https://www.bmj.com/content/395/bmj-2026-100785.short?rss=1#page) ## Follow us on * [X](https://x.com/bmj_latest) * [Facebook](https://www.facebook.com/bmjdotcom) * [Instagram](https://www.instagram.com/the_bmj_) * [Linkedin](https://www.linkedin.com/showcase/the-bmj/) * [YouTube](http://youtube.com/user/BMJmedia) * [RSS](http://feeds.bmj.com/bmj/recent) ## Content links * [Collections](http://www.bmj.com/collections) * [Health in South Asia](http://www.bmj.com/health-in-south-asia) * [Women’s, children’s & adolescents’ health](http://www.bmj.com/content/women%E2%80%99s-children%E2%80%99s-and-adolescents%E2%80%99-health-0) * [Zika virus](http://www.bmj.com/freezikaresources) * [Research](https://www.bmj.com/us/research) * [Education](https://www.bmj.com/us/education) * [News and views](https://www.bmj.com/us/news) * [BMJ Opinion](http://blogs.bmj.com/bmj/) * [Rapid responses](https://www.bmj.com/rapid-responses) * [Archive](https://www.bmj.com/archive) ## About us * [About us](https://www.bmj.com/about-bmj) * [Editorial staff](https://www.bmj.com/about-bmj/editorial-staff) * [BMJ in the USA](https://www.bmj.com/about-bmj/editorial-staff/bmj-united-states) * [BMJ in Latin America](https://www.bmj.com/health-in-latin-america) * [BMJ in South Asia](https://www.bmj.com/about-bmj/editorial-staff/bmj-south-asia) * [Advisers](https://www.bmj.com/about-bmj/advisory-panels) * [Policies](https://www.bmj.com/about-bmj/resources-authors/forms-policies-and-checklists) * [Submit your paper](http://mc.manuscriptcentral.com/bmj) ## Resources * [Authors](https://www.bmj.com/about-bmj/resources-authors) * [Reviewers](https://www.bmj.com/about-bmj/resources-reviewers) * [BMA members](https://www.bmj.com/about-bmj/resources-bma-members) * [Readers](https://www.bmj.com/about-bmj/resources-readers) * [Subscribers](https://www.bmj.com/about-bmj/resources-subscribers) * [Advertisers and sponsors](https://www.bmj.com/about-bmj/resources-advertisers-and-sponsors) * [Media](https://www.bmj.com/about-bmj/resources-media) * [Recruiters](https://recruiter.bmj.com/) ## Explore BMJ * [Our company](https://www.bmj.com/company/?int_source=tbmj&int_medium=footer&int_campaign=URLswitch) * [BMJ Careers](https://jobs.bmj.com/) * [BMJ Learning](http://learning.bmj.com/) * [BMJ Masterclasses](http://masterclasses.bmj.com) * [BMJ Journals](http://journals.bmj.com) * [BMJ Student](https://www.bmj.com/student) * [Academic edition of The BMJ](http://www.bmj.com/about-bmj/resources-readers) * [BMJ Best Practice](http://bestpractice.bmj.com/) * [The BMJ Awards](http://thebmjawards.bmj.com/home) ## My account * [Email alerts](http://myaccount.bmj.com/myaccount/account/hw-registration.html) * [Activate subscription](http://journals.bmj.com/cgi/activate) ## Information * [Contact us](https://www.bmj.com/about-bmj/contact-us) * [Complaints](https://www.bmj.com/about-bmj/complaints-procedur
## Related Clinical Research

- [Neoadjuvant durvalumab plus chemotherapy in resectable NSCLC: results from the phase 2 MDT-BRIDGE](https://medichelpline.com/clinical-feed/nature-0-neoadjuvant-durvalumab-plus-chemotherapy-in-resectable-or-borderline-resectable.md)
- [FDA Oncology Approvals 2014–2025: Immunotherapy vs Non‑Immunotherapy Endpoints and Efficacy](https://medichelpline.com/clinical-feed/medrxiv-1-usfda-oncology-drug-approvals-from-2014-2025-comparing-non-immunotherapy-and.md)
- [Neoadjuvant nivolumab plus visugromab in MIBC: phase 2a GDFATHER-NEO findings](https://medichelpline.com/clinical-feed/nature-0-neoadjuvant-nivolumab-with-or-without-visugromab-in-muscle-invasive-bladder.md)
- [Circulating Tumor DNA to Predict Response to Radiotherapy and Pembrolizumab in Localized Sarcomas](https://medichelpline.com/clinical-feed/pubmed-42715505.md) (DOI: 10.1200/JCO-26-00769)
- [Durability of Disease-free Survival with Adding Belzutifan to Adjuvant Pembrolizumab in RCC: Recon](https://medichelpline.com/clinical-feed/medrxiv-3-does-the-disease-free-survival-benefit-of-adding-belzutifan-to-adjuvant.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.